

**In the Claims**

Please amend the claims as follows. Applicants present a full set of claims showing markups of the claims with insertions and deletions indicated by underlining and strikethrough text, respectively.

1-28. (Canceled)

29. (Currently amended) A composition comprising  
DAPH1 (4,5-dianilinophthalimide), and  
one or more non-NMDA channel antagonists ~~compounds that decrease calcium influx of neuronal cells caused by aggregated  $\beta$ -amyloid ( $A\beta$ ) protein degradation products.~~

30-48. (Canceled)

49. (Currently amended) A composition comprising  
DAPH1 (4,5-dianilinophthalimide) ~~The composition of claim 29, wherein the compound that decreases calcium influx of neuronal cells caused by aggregated  $\beta$ -amyloid ( $A\beta$ ) protein degradation products is and~~ NBQX (2,3-dihydroxy-nitro-7-sulfamoyl-benzo[f]quinoxaline).

50. (New) The composition of claim 29, wherein the non-NMDA channel antagonists are 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), 6,7-dinitroquinoxaline-2,3(1H, 4H)-dione (DNQX), 2,3-dihydroxy-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX), 1-(4-chlorobenzoyl)piperazine-2,3-dicarboxylic acid (CBPD), 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid (24c), Evans blue, 2,3-dihydroxy-7-sulfamoyl-benzo[f]quinoxaline (BQX), derivatives of 4-oxo-1,4-dihydroquinoline-2-carboxylic acid at the 6-position, 2-amino-3-[3-(carboxymethoxy)-5-methylisoxazol-4-yl]propionic acid (AMOA), 2-amino-3-[2-(3-hydroxy-5-methylisoxazol-4-yl)-methyl-5-methyl-3-++oxoisoxazolin-4-yl]propionic acid (AMNH), 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiazepine (GYKI 52466), 6-(1H-imidazol-1-yl)-7-nitro- 2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K), 1-(4-aminophenyl)- 3-methylcarbamyl-4-methyl-7,8-methylenedioxy-3,4

-dihydro-5H-2,3-benzodiazepine (GYKI 53655), and/or

(-)(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-  
decahydroisoquinoline-3-carboxylic acid monohydrate (LY326325)